Establishment and characterization of a novel multidrug-resistant pancreatic ductal adenocarcinoma cell line, PDAC-X1
Cheng Yu,
Yuanhui Su,
Xin Miao,
Changpeng Chai,
Huan Tang,
Lu Li,
Jianfeng Yi,
Zhenzhen Ye,
Hui Zhang,
Zhao Hu,
Luyang Chen,
Ning Li,
Hao Xu,
Wence Zhou
Affiliations
Cheng Yu
The Second Clinical Medical School, Lanzhou University
Yuanhui Su
The Second Clinical Medical School, Lanzhou University
Xin Miao
The First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Provincial Hospital of Chinese Medicine, Zhejiang Chinese Medical University
Changpeng Chai
The Second Clinical Medical School, Lanzhou University
Huan Tang
The Second Clinical Medical School, Lanzhou University
Lu Li
The Fourth Department of General Surgery, The First Hospital of Lanzhou University
Jianfeng Yi
The First Clinical Medical School, Lanzhou University
Zhenzhen Ye
The Second Clinical Medical School, Lanzhou University
Hui Zhang
The Second Clinical Medical School, Lanzhou University
Zhao Hu
The First School of Clinical Medicine, Zhejiang Chinese Medical University
Luyang Chen
The First School of Clinical Medicine, Zhejiang Chinese Medical University
Ning Li
The First School of Clinical Medicine, Zhejiang Chinese Medical University
Hao Xu
The First School of Clinical Medicine, Zhejiang Chinese Medical University
Wence Zhou
The Second Clinical Medical School, Lanzhou University
Abstract Drug resistance remains a significant challenge in the treatment of pancreatic cancer. The development of drug-resistant cell lines is crucial to understanding the underlying mechanisms of resistance and developing novel drugs to improve clinical outcomes. Here, a novel pancreatic cancer cell line, PDAC-X1, derived from Chinese patients has been established. PDAC-X1 was characterized by the immune phenotype, biology, genetics, molecular characteristics, and tumorigenicity. In vitro analysis revealed that PDAC-X1 cells exhibited epithelial morphology and cell markers (CK7 and CK19), expressed cancer-associated markers (E-cadherin, Vimentin, Ki-67, CEA, CA19-9), and produced pancreatic cancer-like organs in suspension culture. In vivo analysis showed that PDAC-X1 cells maintained tumorigenicity with a 100% tumor formation rate. This cell line exhibited a complex karyotype, dominated by subtriploid karyotypes. In addition, PDAC-X1 cells exhibited intrinsic multidrug resistance to multiple drugs, including gemcitabine, paclitaxel, 5-fluorouracil, and oxaliplatin. In conclusion, the PDAC-X1 cell line has been established and characterized, representing a useful and valuable preclinical model to study the underlying mechanisms of drug resistance and develop novel drug therapeutics to improve patient outcomes.
